Formation Bio has announced a $600 million fund to acquire or license clinical-stage drug programs and advance them with the company’s AI-supported development platform. It aims to pursue 10 to 15 programs over the next three to five years, with major clinical milestones targeted within two to four years of acquisition, depending on each program. Formation Bio’s announcement
Continue reading
The rest of this article is for AI News Blitz readers. Choose an option below to keep reading.
Already purchased? Sign in✓ Signed in — this article isn’t included in your current plan.